49.94

0.32% 0.16

Bio Techne Corp (TECH)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Bio Techne Corp stock is traded at $49.94, with a volume of 3.17M. It is up +0.32% in the last 24 hours and down -7.64% over the past month. Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Previous Close:

$49.78

Open:

$50

24h Volume:

3.17M

Relative Volume:

1.54

Market Cap:

$7.98B

Revenue:

$1.17B

Net Income/Loss:

$150.71M

P/E Ratio:

53.13

EPS:

0.94

Net Cash Flow:

$245.03M

1W Performance:

-1.09%

1M Performance:

-7.64%

6M Performance:

-34.25%

1Y Performance:

-37.28%

1-Day Range:

$49.78

$50.77

1-Week Range:

$46.77

$51.04

52-Week Range:

$46.01

$85.57

Bio Techne Corp Stock (TECH) Company Profile

Name

Bio Techne Corp

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

(612) 379-8854

Address

614 MCKINLEY PL N E, MINNEAPOLIS, MN

Employee

3,100

Twitter

@biotechne

Next Earnings Date

2024-10-30

Latest SEC Filings

TECH's Discussions on Twitter

Compare TECH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TECH Bio Techne Corp	49.94	7.98B	1.17B	150.71M	245.03M	0.94
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Bio Techne Corp Stock (TECH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-09-25	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Mar-18-25	Initiated	Evercore ISI	Outperform
Feb-19-25	Downgrade	Robert W. Baird	Outperform → Neutral
May-22-24	Downgrade	Citigroup	Buy → Neutral
Feb-08-24	Initiated	Scotiabank	Sector Outperform
Feb-02-24	Downgrade	Stifel	Buy → Hold
Dec-07-23	Initiated	UBS	Buy
Aug-28-23	Initiated	William Blair	Outperform
Jan-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Dec-14-22	Initiated	Deutsche Bank	Buy
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Dec-07-22	Initiated	RBC Capital Mkts	Sector Perform
Aug-25-22	Initiated	Credit Suisse	Outperform
Apr-25-22	Downgrade	Wells Fargo	Equal Weight → Underweight
Sep-15-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Mar-08-21	Upgrade	Stephens	Equal-Weight → Overweight
Feb-23-21	Upgrade	Stifel	Hold → Buy
Jan-25-21	Reiterated	The Benchmark Company	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-30-20	Initiated	Atlantic Equities	Overweight
Jul-15-20	Downgrade	Stephens	Overweight → Equal-Weight
May-27-20	Downgrade	Stifel	Buy → Hold
May-14-20	Initiated	The Benchmark Company	Buy
Jan-08-20	Resumed	Stephens	Overweight
Jan-08-20	Initiated	Wells Fargo	Equal Weight
Jan-07-20	Initiated	Citigroup	Neutral
Nov-15-19	Initiated	Stifel	Buy
Jul-02-19	Upgrade	Janney	Neutral → Buy
Jan-14-19	Upgrade	Stephens	Equal-Weight → Overweight
Oct-31-18	Downgrade	Craig Hallum	Buy → Hold
Oct-17-18	Initiated	Goldman	Neutral
Jun-15-18	Initiated	Argus	Buy
Jul-13-17	Initiated	Wells Fargo	Market Perform
Feb-09-17	Initiated	Citigroup	Buy
Jan-18-17	Initiated	Deutsche Bank	Buy
Nov-10-16	Resumed	Leerink Partners	Outperform
Jan-21-15	Reiterated	Robert W. Baird	Outperform
Sep-20-13	Upgrade	Robert W. Baird	Neutral → Outperform

View All

Bio Techne Corp Stock (TECH) Latest News

02:28 AM

When the Price of (TECH) Talks, People Listen - news.stocktradersdaily.com

02:28 AM

May 09, 2025

Bio-Techne (TECH) Target Price Lowered to $70 by UBS Analyst | T - GuruFocus

May 09, 2025

UBS Adjusts Price Target on Bio-Techne to $70 From $95, Maintains Buy Rating - marketscreener.com

May 09, 2025

Bio-Techne outlines 2025 growth drivers with NIH uncertainty and strong Protein Sciences performance - MSN

May 09, 2025

Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Corp (TECH) - GuruFocus

May 09, 2025

May 08, 2025

Bio-Techne, Kytopen collaborate on integrated cellular engineering workflow - TipRanks

May 08, 2025

Bio-Techne (TECH) Target Price Lowered by RBC Capital | TECH Stock News - GuruFocus

May 08, 2025

Benchmark Adjusts Bio-Techne Price Target to $75 From $95 - marketscreener.com

May 08, 2025

Bio-Techne (TECH): Benchmark Analyst Lowers Target Price but Maintains Buy Rating | TECH Stock News - GuruFocus

May 08, 2025

BIO-TECHNE (TECH): Analyst Maintains Hold Rating, Lowers Price Target | TECH Stock News - GuruFocus

May 08, 2025

Bio-Techne to Present at the BofA Securities 2025 Health Care Conference - StreetInsider

May 08, 2025

Kytopen and Bio-Techne Collaborate on an Integrated Cellular Eng - GuruFocus

May 08, 2025

Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing | TECH Stock News - GuruFocus

May 08, 2025

Bio-Techne price target lowered to $63 from $72 at RBC Capital - TipRanks

May 08, 2025

Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing - Stock Titan

May 08, 2025

Bio-Techne Corporation (NASDAQ:TECH) Q3 2025 Earnings Call Transcript - Insider Monkey

May 08, 2025

Bio-Techne to Present at the BofA Securities 2025 Health Care Conference | TECH Stock News - GuruFocus

May 08, 2025

RBC Cuts Price Target on Bio-Techne to $63 From $72, Keeps Sector Perform Rating - marketscreener.com

May 08, 2025